In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Samsca (Otsuka)
- INDICATIONS: Chronic heart failure, hyponatremia, polycystic kidneys
- CLASS: Vasopressin receptor antagonist
- HALF-LIFE: 6–8 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aprepitant, Barbiturates, Benazepril, Captopril, Carbamazepine, Clarithromycin, Conivaptan, Cyclosporine, Darunavir, Delavirdine, Digoxin, Efavirenz, Enalapril, Fosinopril, Grapefruit Juice, Indinavir, Irbesartan, Itraconazole, Ketoconazole, Lapatinib, Lisinopril, Lovastatin, Miconazole, Nefazodone, Nelfinavir, Olmesartan, Oxcarbazepine, P-gp inhibitors, Phenytoin, Quinapril, Ramipril, Rifabutin, Rifampin, Rifapentin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A inhibitors, Telithromycin, Voriconazole
March 2013. The U.S. Food and Drug Administration (FDA) has determined that tolvaptan should not be used for longer than 30 days and should not be used in patients with underlying liver disease because it can cause liver injury, potentially requiring liver transplant or death.
INITIATE AND RE-INITIATE IN A HOSPITAL AND MONITOR SERUM SODIUM
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Page last updated 04/16/2024
